PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'UCB Biopharma SRL, Braine-l\'Alleud, Belgium.\', \'Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.\', \'Center for Public Health Genomics, University of Virginia, Charlottesville, Virginia, USA.\', \'GlaxoSmithKline, Stevenage, UK.\', \'GlaxoSmithKline, Collegeville, Pennsylvania, USA.\', \'B\'SYS GmbH, Witterswil, Switzerland.\', \'Certara UK Ltd, Sheffield, UK.\', \'Charles River, Cleveland, Ohio, USA.\', \'Department of Computer Science, University of Oxford, Oxford, UK.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1111/cts.13011
?:doi
?:hasPublicationType
?:journal
  • Clinical and translational science
is ?:pmid of
?:pmid
?:pmid
  • 33620150
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.669
?:rankingScore_hIndex
  • 31
is ?:relation_isRelatedTo_publication of
?:title
  • Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off-label in the first wave of COVID-19.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33620150>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33620150>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all